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Growing evidence has indicated that iron deposition in the substantia nigra plays an 
important role in Parkinson’s disease (PD). However, the underlying mechanism is 
still elusive. Using primary dopaminergic neurons and SH-SY5Y cells cultured in vitro, 
we observed that iron loading increased α-synuclein and reactive oxygen species 
(ROS) levels in these cells but did not affect the intracellular α-synuclein mRNA levels. 
Furthermore, iron loading significantly downregulated Beclin-1 levels and decreased the 
ratio of microtubule-associated protein 1 light chain 3 isoforms (LC3 II/LC3 I). However, 
a significant change in the levels of autophagy-related gene 5 (Atg5) was not observed 
in either neurons or SH-SY5Y cells after iron treatment. After treatment with rapamycin, 
the iron loading-induced increase in the α-synuclein level was significantly reversed and 
ROS generation was alleviated in both cultured neurons and SH-SY5Y cells. These 
results indicate that the inhibition of autophagy is critical for the pathological alterations 
in α-synuclein induced by iron loading. Moreover, treatment with vitamin E did not 
affect the increase in the α-synuclein levels but significantly eliminated the iron-induced 
ROS production. Together, our study shows that autophagy dysfunction contributes to 
iron-induced α-synuclein pathology.
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inTrODUcTiOn
Parkinson’s disease (PD) is one of the most common movement disorders. PD is clinically character-
ized by resting tremor, rigidity, and bradykinesia and is pathologically characterized by the aberrant 
accumulation of α-synuclein and dopaminergic neuron loss in the substantia nigra pars compacta 
(1–3). The etiology and pathogenesis of PD are still largely unknown, and an effective therapy 
against disease progression has not been achieved. Thus, more efforts are needed to characterize the 
pathological etiology of PD.
Since Lhermitte’s first report in 1924 that iron content was increased in the midbrain of individu-
als with PD (4), the role of iron deposition in PD progression has received substantial attention 
(5–9). As described in previous studies by our and other groups, an elevated nigral iron level is 
correlated with the disease severity in patients with PD (7, 10). Accumulating evidence from in vitro 
studies has revealed that the expression of human α-synuclein is modified by iron deposition, which 
subsequently results in the aggregation and toxicity of α-synuclein (11, 12). Furthermore, an iron 
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chelation treatment was shown to benefit patients with PD; 
substantia nigra (SN) iron levels were decreased and clinical and 
radiological improvements were observed (13). Many other stud-
ies have also indicated that elevated iron levels in the SN present 
a tractable target for PD (14, 15). Together, these results indicate 
that the aberrant accumulation of iron is crucial in PD progres-
sion. However, the mechanism underlying the iron-induced 
development of PD is still elusive.
Oxidative stress has been demonstrated to be an important 
factor in iron-induced pathologies, serving as a link between 
iron deposition and PD (16, 17). Elevated iron levels in the SN 
lead to the generation of reactive oxygen species (ROS), such as 
superoxide anion radicals and hydroxyl radicals; the increase in 
ROS level subsequently results in the aberrant upregulation of 
α-synuclein and damage to dopaminergic neurons in PD (16, 17). 
In the presence of iron, the highly reactive hydroxyl radical is 
produced by the Fenton reaction (16). As one of the most harm-
ful ROS, this highly reactive hydroxyl radical damages proteins, 
nucleic acids, and the lipid membrane, resulting in cell injury and 
death (16). Nevertheless, controversy still exists. Oxidative stress 
is not considered a determining factor of the aberrant aggregation 
of α-synuclein in PD. Radical eliminators thoroughly remove 
the generated ROS in  vitro but are unable to entirely reverse 
the iron-induced upregulation of α-synuclein (18). Moreover, 
anti-oxidants have little effect on improving the symptoms of PD 
(19–21). Thus, other potential mechanisms might be involved in 
the development of PD.
Autophagy is a degradation process that plays a pivotal role in 
the cellular energy balance and in eliminating misfolded proteins 
in cells (22). Autophagy is classified as macroautophagy, micro-
autophagy, and chaperone-mediated autophagy (CMA) (23, 24). 
In the last decade, growing evidence has indicated an intimate 
relationship between autophagy and PD, showing that autophagy 
dysregulation may play a critical role in the development of PD. 
Aggregates of α-synuclein are mainly degraded via the autophagy 
pathway (25–27), including macroautophagy and CMA pathways 
(24). The autophagy signaling pathway has been reported to be 
disrupted in PD (28). Furthermore, the inhibition of autophagy 
results in the pathological accumulation of α-synuclein in neu-
rons (28). However, the role of autophagy in iron-induced PD 
pathology remains unclear.
In this study, we investigated the effect of iron deposition 
on neural cells and then evaluated the role of autophagy in the 
pathological, iron-induced accumulation of α-synuclein.
MaTerials anD MeThODs
cell culture and Treatments
SH-SY5Y cells (Type Culture Collection of the Chinese 
Academy of Sciences, Shanghai, China) were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM, Gibco, USA) 
supplemented with 10% fetal bovine serum (Gibco, USA), 
100 U/ml penicillin, and 100 µg/ml streptomycin (Gibco, USA) 
at 37°C in a humidified atmosphere containing 5% CO2. The 
cells were subcultured every 3 days and were grown to 70–80% 
confluence prior to treatment.
The primary mesencephalic cells were cultured using a previ-
ously described method (29) with several modifications. Briefly, 
on day 17, pregnant Sprague-Dawley (SD) rats were anesthetized, 
and the fetuses were collected to isolate and digest the cells. The 
mesencephalic dopaminergic region was retrieved. Cell suspen-
sions were filtered, centrifuged, and plated onto poly-l-lysine-
coated dishes at a density of 5 ×  104  cells/cm2. Approximately 
5  h later, the medium was replaced with neurobasal medium 
supplemented with B27 and GlutaMAX (Invitrogen, USA). 
The cells were maintained for 12 days before administering the 
indicated treatment. This procedure used to collect primary cells 
from SD rats employed in this study was approved by the Medical 
Experimental Animal Administrative Committee of Zhongshan 
Hospital, Fudan University.
Cells were treated with ferrous chloride (Sigma, USA) prepared 
in sterilized water containing 0.01 N HCl as previously described 
(30). Rapamycin (InvivoGen, USA) was dissolved in DMSO 
(Sigma, USA) as a 10 mM sterile stock solution, and 0.2 µM was 
employed as the working concentration of rapamycin, according 
to the manufacturer’s instructions and previously published work 
(31, 32). Vitamin E (Sigma, USA) was used as an ROS scavenger 
as previously described (18, 33). The cells were incubated with the 
indicated agents for 24 h and then were harvested for detection.
Knockdown of α-synuclein with small 
interfering rnas (sirnas)
Cholestenone-modified siRNAs targeting rat α-synuclein 
5′-CCTCTATGTAGGTTCCAAA-3′ was synthesized by BioTend 
(China). Twenty-four hours before the iron treatment, the neu-
rons were transfected with the siRNAs using the Lipofectamine® 
RNAiMAX Transfection Reagent (Invitrogen, USA) according to 
the manufacturer’s instructions.
Measurement of cell Viability
Cell viability was measured using a CKK-8 assay according to the 
manufacturer’s instructions (Dojindo, Japan). Three hours after 
the CCK-8 solution was added, the absorbance was determined at 
450 nm using a microplate reader (Thermo Fisher, USA).
immunofluorescent staining
Cells were cultured on a round slide. After treatment, the slide 
was washed with 0.01 M PBS and fixed with 4% PFA as previously 
described (34). The primary antibody (Mouse anti-α-synuclein: 
BD, USA; Rabbit anti-NeuN: Abcam, USA) was added and 
incubated with the cells for 48  h at 4°C. Then, the slide was 
exposed to the Alexa Fluor® antibody (Invitrogen, USA) and 
incubated for 1 h at 37°C. The nucleic acids were stained with 
DAPI (Invitrogen, USA). Following a final wash and mounting 
with anti-fade medium (Sigma, USA), images were acquired 
using a fluorescence microscope (Nikon, Japan). The fluorescence 
intensity was determined using Image-Pro Plus, Version 6.0 
(MediaCybernetics, Inc., USA).
Western Blots
Western blotting was conducted as previously described (35, 
36). After an incubation with the indicated antibodies (Beclin-1, 
TaBle 1 | Pcr primers.
genes of interest gene iD sequence (5′ → 3′)
Human SCNA 6622 Forward AAGAGGGTGTTCTCTATGTAGGC
Reverse GCTCCTCCAACATTTGTCACTT
Human β-actin 60 Forward CATGTACGTTGCTATCCAGGC
Reverse CTCCTTAATGTCACGCACGAT
Rat SCNA 29219 Forward AAGGGTACCCACAAGAGGGA
Reverse AACTGAGCACTTGTACGCCA
Rat β-actin 81822 Forward CATCCGTAAAGACCTCTATGCC
Reverse AGGATAGAGCCACCAATCCAC
3
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Atg5, and LC3 I/II: CST, USA; α-synuclein: BD Biosciences, USA; 
GAPDH: Santa Cruz Biotechnology, USA), the membranes were 
analyzed, and images were captured using an Odyssey infrared 
fluorescence imaging system (LI-COR, USA).
real-time qPcr
Quantitative PCR was conducted using our previously described 
method (36), and the 2−ΔΔCT method was used to analyze the fold 
change in the levels of the α-synuclein mRNA. The forward and 
reverse sequences of the PCR primers are listed in Table 1.
Measurement of intracellular rOs levels
The levels of oxidative stress were evaluated using an ROS detec-
tion kit (Invitrogen, USA), and the procedure was conducted 
according to the manufacturer’s instructions. The relative fluores-
cence intensity of the cells was quantified using a multi-detection 
microplate reader (Bio-Rad, USA) at an excitation wavelength of 
488 nm and an emission wavelength of 525 nm. The intracellular 
ROS levels were expressed as a percentage of the control cells.
Transmission electron Microscopy (TeM)
Transmission electron microscopy was performed using a pre-
viously described method (37). Briefly, the cells were pre-fixed 
with ice-cold 2.5% glutaraldehyde (Sigma, USA) diluted in 
0.1 M phosphate-buffered saline and post-fixed with 1% osmium 
tetroxide buffer. After dehydration in a gradient series of ethyl 
alcohol, the cells were embedded in epoxy resin. Ultrathin sec-
tions (60-nm thick) were stained with uranyl acetate and lead 
citrate and examined using a transmission electron microscope 
(Philips CM120, the Netherlands).
statistical analysis
All results are expressed as the means ± SD. Statistical analyses 
were performed using GraphPad Prism 5.0 software (GraphPad 
Software, Inc., USA). All experiments were independently 
repeated three times. The statistical significance of the differences 
among different groups was analyzed using one-way analysis of 
variance or Student’s t-test, in which p <  0.05 was considered 
significant.
resUlTs
iron Decreased cell Viability
As shown in Figure 1, primary cultured neurons and SH-SY5Y 
cells exhibited alterations in cell viability following incubation 
with different concentrations of ferrous chloride. After a 24-h 
treatment with 100 µM ferrous chloride, the viability of neurons 
and SH-SY5Y cells was significantly reduced (p <  0.05). The 
viability of neurons and SH-SY5Y cells exhibited a decreasing 
trend that was not significantly different (p > 0.05) after incuba-
tion with 50 µM ferrous chloride. Incubation with 20 µM ferrous 
chloride did not reduce the viability of neurons and SH-SY5Y 
cells. Thus, we employed 20 µM ferrous chloride in the subse-
quent experiments.
iron increased α-synuclein levels and 
rOs generation but Did not affect the 
expression of α-synuclein mrna
To determine whether iron deposition affects α-synuclein levels, 
we evaluated the effect of iron on the changes in the α-synuclein 
levels in primary neurons and SH-SY5Y cells. Using immuno-
fluorescence staining and Western blotting, we observed that 
iron exposure upregulated the levels of α-synuclein protein 
(Figures 2A,B,D,E, p < 0.01 for neurons, p < 0.05 for SH-SY5Y 
cells). However, the iron treatment did not affect the levels of 
α-synuclein mRNA (Figure 2C, p > 0.05).
Consistent with the results from previous studies (38), we also 
observed a 2.6-fold increase in ROS levels in iron-treated cells 
compared with those of the control (Figure 5A, p < 0.05).
iron inhibited autophagy
Alterations in the levels of the autophagy-related proteins in 
both of primary neurons and SH-SY5Y cells, including Beclin1, 
autophagy-related gene 5 (Atg5), and microtubule-associated 
protein 1 light chain 3 isoforms (LC3 I/LC3 II), were examined by 
Western blotting. The iron treatment significantly downregulated 
the levels of Beclin1 (Figures 3A,B, p = 0.01 for neurons, p = 0.02 
for SH-SY5Y cells). Moreover, the levels of LC3 II and the LC3 II/I 
ratio were also significantly decreased (Figures 3A,B, p = 0.01 
for neurons, p = 0.03 for SH-SY5Y cells). However, Atg5 levels 
were not significantly reduced in response to the iron treatment 
(Figures 3A,B, p > 0.05).
Using TEM, we consistently confirmed that the number of 
autophagosomes in the iron-treated neurons was less than the 
number in control neurons or SH-SY5Y cells (Figure 3C).
rapamycin alleviated iron-induced α-
synuclein accumulation and rOs 
generation
To further investigate the role of autophagy inhibition in iron-
induced pathological change in our in vitro work, we employed an 
autophagy activator, rapamycin. Following co-incubation with or 
without iron, rapamycin was observed a slight trend of reduction 
but did not significantly affect the α-synuclein levels in the control 
groups (Figures 4A,C,D, p > 0.05); however, the upregulation of 
the α-synuclein levels induced by iron was ameliorated by the 
rapamycin treatment (Figures 4A,C,D, p < 0.05).
We then evaluated the levels of oxidative stress in rapamycin-
treated neurons. As shown in Figure 4, rapamycin potently elimi-
nated iron-induced ROS generation (Figures 4G,H, p < 0.01) as 
compared with the iron treatment alone.
FigUre 2 | iron increased the levels of the α-synuclein protein but did not affect the expression of the α-synuclein mrna. After a 24-h iron treatment, 
cells were harvested to examine the protein and mRNA levels. As shown above, the iron treatment increased the level of the α-synuclein protein [α-Syn (a,D), 
p < 0.05] but did not affect the levels of the α-Syn mRNA [(c), p > 0.05]. (B,e) show the quantitation of the data shown in (a,D), respectively. The results are 
presented as means ± SD, and Student’s t-test was used to determine the statistical significance of the differences.
FigUre 1 | effect of iron on cell viability. The effects of different concentrations of iron on cell viability were determined using the CCK-8 assay. Iron 
concentrations greater than 50 µM led to significant cell damage. Iron concentrations greater than 100 µM induced marked toxicity to both primary neurons (a) and 
SH-SY5Y cells (B). The results are presented as means ± SD, and one-way analysis of variance was employed to determine the statistical significance of the 
differences. *p < 0.05 vs. the control.
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Vitamin e eliminated iron-induced rOs 
generation but Did not alleviate  
α-synuclein Pathology
As mentioned above, the iron treatment increased the ROS 
levels in  vitro, indicating that iron induced oxidative stress. 
To determine whether the ROS eliminator vitamin E could influ-
ence the iron-induced oxidative stress and α-synuclein pathology, 
we tested the effects of different concentrations of vitamin E on 
primary neurons. At concentrations ranging from 1 to 10  µM, 
the vitamin E treatment reduced iron-induced ROS generation in 
neurons (Figure 5A, p < 0.05). In the presence of 1 µM vitamin E, 
FigUre 3 | iron inhibited autophagy. The levels of the Beclin-1 (p < 0.05) and Atg5 proteins (p > 0.05) were decreased in iron-treated cultures (a). The LC3 II 
level was also decreased and the LC3II/I ratio was reduced in the iron-treated cells [(a), p < 0.05]. (B) shows the quantitation of the results shown in (a). (c) shows 
the autophagosomes present in primary neurons. The results are presented as means ± SD, and Student’s t-test was used to determine the statistical significance 
of the differences.
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the ROS levels were significantly decreased compared with those 
of cells treated with iron alone and of the control (Figure  5A, 
p = 0.03). However, following treatment with 2 µM vitamin E, 
the ROS levels were not significantly different from the control 
(Figure 5A, p > 0.05).
Primary neurons were then treated with 20  µM iron in the 
presence and absence of 2 µM vitamin E to analyze the effect of 
oxidative stress on the elevated α-synuclein levels. As shown in 
Figures 5B–E, incubation with vitamin E alone did not affect the 
α-synuclein levels in neurons or the iron-induced upregulation of 
the α-synuclein levels (p > 0.05). Although iron-induced oxida-
tive stress was inhibited in vitro, the increased α-synuclein levels 
were not reduced by vitamin E.
α-synuclein silencing Did not affect the 
iron-induced inhibition of autophagy
According to previous reports, the pathological changes in 
α-synuclein, such as its overexpression and formation of oligom-
ers, inhibit autophagy (39, 40). As shown in this work, iron depo-
sition led to dysfunctional autophagy and α-synuclein pathology. 
We then transfected neurons with siRNAs targeting α-synuclein 
to determine whether the inhibition of autophagy was directly 
mediated by iron or by the increase in the level of the α-synuclein 
protein. First, the α-synuclein levels were determined in cells 
transfected with the siRNAs using Western blotting (Figure 6A, 
p < 0.01). Subsequently, we evaluated the changes in the levels 
of autophagic proteins including Beclin1, Atg5, and LC3 II/LC3 
I in iron-treated neurons within siRNAs transfection. The iron-
induced downregulation of the Beclin-1, Atg5, and LC3 II levels 
was not significantly changed by the silencing of α-synuclein 
compared with the effects seen in the iron-treated neurons 
(Figures 6B–D, p > 0.05).
DiscUssiOn
The mechanisms underlying abnormal α-synuclein aggregation 
in dopaminergic neurons in patients with PD are elusive and 
require further investigation. Iron accumulation in the brain has 
been implicated in PD (5–9), but our current understanding of 
this phenomenon is very limited. Substantial evidence suggests a 
robust link between iron deposition in the SN and the pathologi-
cal lesions observed in patients with PD (11, 12, 14, 15). As shown 
in this study, iron-treated neuronal cells exhibited α-synuclein 
aggregates and the autophagy signaling pathway was inhibited. 
Following an incubation with rapamycin, the iron-induced 
pathologies of α-synuclein aggregation and ROS generation were 
alleviated by the activation of autophagy, suggesting a critical role 
for autophagy in PD.
Oxidative stress results from an imbalance between ROS gen-
eration and the intracellular detoxifying systems (16). Oxidative 
FigUre 4 | continued
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FigUre 5 | Vitamin e eliminated reactive oxygen species (rOs) production but did not alleviate iron-induced α-synuclein pathology in neurons. 
Vitamin E (Vit E), an ROS eliminator, was added to the cultures to evaluate the role of oxidative stress in iron-induced pathology in neurons. ROS production was 
completely eliminated by Vit E (a). However, the iron-induced increase in the α-Syn levels was not reduced by the elimination of ROS production (B,D). (c,e) show 
the quantitation of the results presented in (B,D), respectively. The results are presented as means ± SD, and one-way analysis of variance was employed to 
determine the statistical significance of the differences. **p < 0.05 vs. the control.
FigUre 4 | continued 
rapamycin alleviated the iron-induced pathological changes, including α-synuclein accumulation and reactive oxygen species (rOs) production. 
Rapamycin (Rapa) was used to activate autophagy in neurons. Compared with the iron treatment alone, Rapa significantly reversed the upregulation of α-Syn 
[(a,c,D), p < 0.05] and reduced ROS production in the cells [(g,h), p < 0.05]. (a,c,g) show the data obtained from primary neurons; (D,h) show the data obtained 
from SH-SY-5Y cells. (B,e,F) show the quantitation of the data shown in (a,c,D), respectively. (i) shows the effect of Rapa on cell viability performing that the 
concentration of 0.2 µM did not affect cell viability in vitro (p > 0.05). The results are presented as means ± SD, and one-way analysis of variance was employed to 
determine the statistical significance of the differences.
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stress has been shown to be an important component of the iron-
induced pathological changes, and some researchers posited that 
oxidative stress is a vital factor that contributes to α-synuclein 
pathology in PD (16, 17). However, recent evidence has revealed 
that oxidative stress is not responsible for iron-induced lesions 
in PD (18), suggesting that the effects of oxidative stress on PD 
might require re-evaluation. We also achieved a similar result 
in  vitro in this study, as the vitamin E treatment eliminated 
ROS but was unable to reverse the iron-induced upregulation of 
α-synuclein. Our results are consistent with those of a previously 
published study by Li et  al. who reported that the elimination 
of iron-induced ROS production only partially alleviated the 
intracellular α-synuclein aggregation in SK-N-SH cells (18). In 
previous studies, the administration of anti-oxidant drugs did not 
confer any protective effects on attenuating the risk of PD (20). 
Furthermore, a randomized clinical trial showed that a high dos-
age of anti-oxidants had a finite benefit for patients with PD (19). 
These results compelled us to examine the mechanisms underly-
ing iron-induced PD-like pathology, in which other mechanisms 
may be involved.
Autophagy is an intracellular catabolic program that is active 
under normal and pathological conditions. It is executed by 
multiple autophagy-related proteins, including Beclin1, LC3I/II, 
Atg5, and others (41). This process degrades damaged proteins 
and organelles via the autophagy–lysosome pathway and ubiqui-
tin–proteasome system, plays an essential role in the survival of 
cellular organisms, and provides the necessary materials for cells 
for cells to compensate for stress conditions such as starvation 
(41). Excessive activation of autophagy is considered pernicious 
and has been determined to contribute to neuronal death (42). 
FigUre 6 | iron-induced inhibition of autophagy was not attenuated by α-synuclein silencing in neurons. The effect of small interfering RNAs (siRNAs) 
targeting α-synuclein was determined using Western blotting (a). (B) shows that silencing of α-synuclein did not affect iron-induced inhibition of autophagy.  
(c,D) show the quantitation of the results presented in (a,B), respectively. The results are presented as means ± SD, and one-way analysis of variance was 
employed to determine the statistical significance of the differences. **p < 0.05 vs. the negative control (NC).
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The disruption of autophagy is also harmful, resulting in the 
accumulation of misfolded proteins and dysfunctional organelles 
in cells (43, 44). The coordination of autophagic functions, 
including activation and inhibition, ensures the balance between 
cell growth and death. Thus, autophagy is not only critical for 
cellular survival and normal function but also plays dual roles in 
cellular life and death (45).
Numerous studies have indicated that autophagy is involved 
in the pathological changes observed in PD (25–27). However, 
the explicit role of autophagy in iron-induced pathology is still 
uncertain. As shown in this study, iron led to α-synuclein pathol-
ogy in neurons by disrupting Beclin-1-dependent autophagy. 
Although numerous signaling pathways, including oxidative 
stress, have been shown to contribute to the progression of PD, 
the pathogenesis of the disease remains to be clarified. Impaired 
autophagy has been shown to be involved in the pathological 
changes in α-synuclein in PD (46–48). As shown in this study, 
iron loading resulted in α-synuclein accumulation and impaired 
autophagy in both primary neurons and SH-SY5Y cells. The iron 
treatment significantly decreased the levels of the Beclin1 and 
Atg5 proteins. In addition, the LC3 II level and LC II/I ratio were 
significantly decreased. Rapamycin significantly reversed the 
iron-induced upregulation of the neuronal α-synuclein levels by 
activating the autophagy pathway. Furthermore, rapamycin also 
ameliorated iron-induced ROS generation in neurons, indicating 
that disruptions in autophagy were involved in iron-induced 
oxidative stress. Additionally, α-synuclein silencing in primary 
neurons transfected with siRNAs did not affect the iron-induced 
inhibition of autophagy, suggesting that the iron treatment pri-
marily disrupted autophagy but not the subsequent pathological 
changes in the α-synuclein levels. Together, our data indicate 
that iron-induced autophagy dysfunction may be responsible for 
α-synuclein accumulation. Moreover, iron deposition alone may 
directly inhibit the autophagy signaling pathway. However, we 
still cannot conclude that the pathological changes in α-synuclein 
observed in this work do not affect the function of the autophagy 
pathway because the toxic effects of α-synuclein, including the 
inhibition of autophagy, might be masked by the changes induced 
by the iron treatment.
In conclusion, autophagy is critical for the iron-induced 
pathogenesis of PD. Oxidative stress is also associated with 
α-synuclein accumulation but may not play the key role in iron-
induced α-synuclein pathology in PD. Normally, autophagy is an 
important contributor to intracellular homeostasis; thus, main-
taining proper activity of the autophagy pathway is essential for 
eliminating aberrant protein aggregates. Based on the data from 
this study, the regulation of autophagy is a potential therapeutic 
target for PD. However, further investigation is still needed to 
clarify the role of the autophagy pathway in PD, particularly in 
in vivo models and in patients.
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